KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT.

Nelson J Chao

Blood blood.2026035591

PMID42826158
PMCID-
DOI10.1182/blood.2026035591
发表日期2026-10-02
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and infection. The engineered graft appears to instruct immune reconstitution toward a regulated, tolerance-associated state, giving the product a mechanism for further studies. The question is how far we can further program it.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。